SOLICITATION NOTICE
B -- Microdissecting and Evaluating RNA from the SUCCEED Study to Define Host and Viral Gene Expression Patterns of Specific Cervix Cell Population and Disease Status
- Notice Date
- 8/31/2005
- Notice Type
- Solicitation Notice
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-50164-NG
- Response Due
- 9/12/2005
- Archive Date
- 9/27/2005
- Description
- The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis, services regarding: Microdissecting and evaluating RNA from the SUCCEED study to define host and viral gene expression patterns of specific cervix cell population and disease status with The University of Wisconsin ? Madison, 1525 Linden Drive, Madison, WI 53706-1596. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System code is 325413 and the business size standard is 500 employees. The Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) is being conducted to identify host and viral biomarkers that would molecularly distinguish women ?at risk? of progressive cervical neoplasia. The purpose of SUCCEED is to identify biomarkers that would distinguish those women who will progress to cervical neoplasia from the majority that will not. Especially pertinent to the success of the study is the ability to understand the distinctive molecular events that occur in each cervix, comparing tumor cells to parts of the cervix that appear normal. The specific objective of this procurement is to evaluate a sample of SUCCEED tissue specimens collected to date and conduct detailed processing and evaluation of tissue quality, macromolecule recovery (RNA and DNA), and use of recovered macromolecules for relevant assays, namely the Affymetrix U133 Plus 2.0 human genome microarray and the University of Wisconsin at Madison?s in-house human papillomavirus expression array. At present, NCI is unable to predict with any accuracy which HPV infections will progress and which will be among the majority that regress. The purpose of SUCCEED is to therefore identify host and viral biomarkers that would distinguish those women who will proceed to cervical neoplasia from the majority that will not. The University of Wisconsin at Madison presently constructs an in-house HPV array chip that contains 70-mer oligonucleotide probes for all genes of all 37 sequenced mucosotropic HPV genotypes as well as a few selected host genes. The chip has been verified and optimized with various known samples including: HPV-expressing keratinocyte cell lines (NIKS, W12, CaSki), oral cancer-driven cell lines, and primary cancer tissue, showing reliable determination of HPV gene expression and genotypes. Additional capabilities include the detection of non-integrated HPV DNA and the ability to add additional probes as desired, such as spliced mRNA junctions. This HPV chip is produced solely by the University of Wisconsin and the utilization of this chip is critical to the proposed analysis of SUCCEED specimens for host and viral expression. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EDT, on September 12, 2005. For further information please contact Malinda Holdcraft, Contract Specialist via electronic mail at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference NCI-50164-NG.
- Record
- SN00883568-W 20050902/050831211946 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |